VIDEO: Keep online practice information accurate, updated

In this Healio Video Perspective, Cynthia A. Matossian, MD, FACS, and David Evans, PhD, MBA, discuss making sure a practice’s online information is not outdated.
It is important for physicians to research their own practice online to check the accuracy of the content that is presented, Evans said. After any incorrect or out-of-date information is fixed, practice owners should check the accuracy again every 1 to 2 months to ensure that any mistakes do not go unnoticed for long.

Linzess safely improves bowel movement, consistency in pediatric functional constipation

Ironwood Pharmaceuticals Inc. announced positive results from its phase 3 trial that evaluated Linzess for the treatment of pediatric patients with functional constipation, according to a company press release.
In a randomized, double-blind, parallel group study, 330 pediatric patients with functional constipation aged 6 to 17 years received either Linzess (linaclotide 72 mcg, AbbVie/Ironwood) or placebo. In a Healio interview exclusive, Susanna Huh, MD, MPH, head of clinical development and research for Ironwood Pharmaceuticals, said Linzess induced a “statistically significant and

HF diagnosis heightens depression, suicide risk in men, women

Both men and women with HF faced higher risks for depression and death by suicide in the first 3 months after their diagnosis, researchers reported in JACC: Heart Failure.
“The large burden of disease associated with HF may potentially cause psychosocial distress that worsens suffering, quality of life and long-term health outcomes,” Casey Crump, MD, PhD, vice chair for research in the department of family medicine and community health at Mount Sinai, and colleagues wrote. “Previous evidence has shown that HF patients with psychosocial distress are more likely to struggle

Zimmer Biomet receives FDA 510(k) clearance for shoulder replacement system

Zimmer Biomet Inc. has announced FDA 510(k) clearance of the Identity shoulder system for anatomic, reverse and revision shoulder replacement procedures, according to a company press release.
The Identity shoulder system is compatible with a range of humeral and glenoid options to fit each patient’s unique anatomy, according to the release.
“The FDA clearance of the Identity shoulder system is exciting because it offers surgeons a highly adaptable solution for anatomic, reverse and revision procedures to help patients optimize natural shoulder movement,” Ivan Tornos, chief

Combination extends OS in metastatic colorectal cancer

The addition of bevacizumab to trifluridine and tipiracil extended OS among patients with advanced colorectal cancer, according to a topline data announcement.
Trifluridine and tipiracil (Lonsurf; Taiho Oncology, Servier) is an oral agent that utilizes a dual mechanism of action to maintain clinical activity. Trifluridine, an antineoplastic nucleoside analogue, interferes with DNA function. The blood concentration of trifluridine is maintained via tipiracil, an inhibitor of the trifluridine-degrading enzyme thymidine phosphorylase.
The randomized phase 3 SUNLIGHT trial included 492 patients

Disarming the immune system’s lethal lung response

Neutrophils, the most abundant type of white blood cell, are the body's first line of defense against infection. Foreign pathogens can stress the body and activate neutrophils. When activated, neutrophils employ various weapons to protect the body. But if overactivated, these weapons can damage the body's own tissues. Lung tissue is saturated with blood vessels, making them very susceptible to neutrophil attacks. If severe enough, acute lung injuries can lead to acute respiratory distress syndrome (ARDS), the leading cause of death due to COVID-19.

Guidelines describe how non-allergists can de-label penicillin allergies

The British Society for Allergy and Clinical Immunology has released guidelines for clinicians in the U.K. who are not trained in allergy or immunology to evaluate and test patients with an unsubstantiated label of penicillin allergy.
Such clinicians may wish to develop a penicillin allergy de-labeling service for their patients, as 5.6% of the general population in the U.K. has a penicillin allergy label, although about 95% of such labels are incorrect when tested, Louise Savic, MD, consultant anesthetist, department of anesthesia, Leeds Teaching Hospitals, NHS Trust, and colleagues wrote in

Help for Ukrainian colleagues, environmental responsibility at the heart of ESCRS action

MILAN — Support for Ukraine and sustainability are two key projects of the European Society of Cataract and Refractive Surgeons, Oliver Findl, MD, MBA, FEBO, ESCRS president, said at the meeting here.
Besides offering free memberships, observerships and travel grants to Ukrainian colleagues since early in the conflict, ESCRS and industry partners have assisted in facilitating needed supplies, particularly for ophthalmic trauma care.
“From two storage sites, one in Poland and one in the western part of the country, equipment such as slit lamps, vitreoretinal surgery platforms and

Treatment significantly improved symptoms in those with MDD, childhood trauma

In individuals with major depressive disorder and childhood trauma, symptoms improved significantly following pharmacological and psychotherapeutic treatments, regardless of severity, per a study published in Lancet Psychiatry.
“In patients with a history of childhood trauma, depressive disorders, including major depressive disorder, are characterized by earlier onset, greater recurrence, more comorbidity and poorer responses to psychotherapy or pharmacotherapy,” Erika Kuzminskaite, MS, a PhD candidate in the department of psychiatry at Vrije University in the Netherlands, and

ODAC: Duvelisib lacks favorable benefit-risk profile in CLL, small lymphocytic lymphoma

An FDA advisory panel voted 8-4 that duvelisib did not have a favorable benefit-risk profile for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received at least two prior therapies.
The FDA Oncologic Drugs Advisory Committee made its decision after considering an update of the new drug application for the PI3 kinase inhibitor, which has been approved for this patient population.
In June, FDA issued a warning about the potential risk for death and serious adverse events with duvelisib (Copiktra, Secura Bio). Five-year OS data from the DUO